ABUS PEER ANALYSIS

Arbutus Biopharma Corp — metric-by-metric comparison with peers and the industry median

ABUSArbutus Biopharma Corp

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

ABUSIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ABUS	MSB	TLX	RTALB	CSL	Ind. Median
P/E	5.92	—	—	4.89●	29.44	17.91
P/B	3.65	—	6.37	0.61●	2.20	3.51
EV/EBITDA	5.32●	—	120.14	74.61	10.21	14.82
P/S	4.97	31.61	3.24	6.67	2.62●	10.89

Financial Health
Metric	ABUS	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	54.26●	—	1.43	1.21	2.57	5.90
Debt/Equity	0.2%●	—	112.3%	1.2%	67.4%	10.9%
NetDebt/EBITDA	-0.59●	—	13.13	0.90	2.22	1.15

Profitability
Metric	ABUS	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	84.0%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	94.7%●	-11.3%	-1.8%	15.1%	7.7%	-47.5%
ROA	81.5%●	-8.6%	-0.7%	13.1%	3.8%	-35.8%
EBITDA Margin	84.0%●	-76.6%	3.0%	9.0%	32.8%	-105.8%

Growth + Dividend
Metric	ABUS	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	2,889.9%●	410.4%	56.3%	24.0%	4.8%	5.1%
NI Growth	—	—	—	134.0%●	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	ABUS	DSGN	LXRX	JANX	PHAT	KURA	Ind. Median
P/E	5.92	—	—	—	—	—	17.91
P/B	3.65	4.41	4.58	1.03	-2.73●	9.12	3.51
EV/EBITDA	5.32	—	—	—	—	—	14.82
P/S	4.97	—	13.33	45.06	4.49●	13.73	10.89

Financial Health
Metric	ABUS	DSGN	LXRX	JANX	PHAT	KURA	Ind. Median
Current Ratio	54.26●	22.28	18.79	17.01	2.21	6.15	5.90
Debt/Equity	0.2%	1.3%	28.4%	2.3%	-49.4%●	22.5%	10.9%
NetDebt/EBITDA	-0.59●	3.19	6.48	8.31	0.16	1.90	1.15

Profitability
Metric	ABUS	DSGN	LXRX	JANX	PHAT	KURA	Ind. Median
Net Margin	84.0%●	—	-37.5%	-529.7%	-76.8%	-411.2%	-125.7%
ROE	94.7%●	-31.3%	-16.0%	-11.7%	—	-124.7%	-47.5%
ROA	81.5%●	-29.8%	-9.2%	-11.0%	-52.5%	-42.2%	-35.8%
EBITDA Margin	84.0%●	—	-25.0%	-520.3%	-44.4%	-408.0%	-105.8%

Growth + Dividend
Metric	ABUS	DSGN	LXRX	JANX	PHAT	KURA	Ind. Median
Rev. Growth	2,889.9%●	-100.0%	123.1%	2,522.9%	150.3%	5.4%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ABUS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.